NorthRock Partners’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.28M Sell
16,038
-567
-3% -$46.7K 0.02% 258
2025
Q4
$1.42M Sell
16,605
-8,922
-35% -$732K 0.02% 232
2025
Q3
$1.99M Buy
25,527
+2,822
+12% +$220K 0.04% 213
2025
Q2
$1.78M Buy
22,705
+2,650
+13% +$198K 0.05% 144
2025
Q1
$1.45M Sell
20,055
-42
-0.2% -$3.01K 0.05% 154
2024
Q4
$1.49M Buy
20,097
+2,040
+11% +$143K 0.05% 150
2024
Q3
$1.19M Sell
18,057
-1,991
-10% -$145K 0.04% 195
2024
Q2
$1.85M Buy
20,048
+757
+4% +$67K 0.07% 119
2024
Q1
$1.84M Buy
19,291
+640
+3% +$53.8K 0.07% 129
2023
Q4
$1.42M Buy
18,651
+5,149
+38% +$358K 0.06% 149
2023
Q3
$935K Sell
13,502
-1,154
-8% -$92.7K 0.1% 102
2023
Q2
$1.38M Sell
14,656
-527
-3% -$45.8K 0.15% 64
2023
Q1
$1.26M Buy
15,183
+958
+7% +$75.3K 0.13% 73
2022
Q4
$1.06M Sell
14,225
-1,220
-8% -$94K 0.12% 87
2022
Q3
$1.28M Sell
15,445
-595
-4% -$57.3K 0.15% 69
2022
Q2
$1.52M Buy
16,040
+1,753
+12% +$181K 0.16% 70
2022
Q1
$1.68M Sell
14,287
-2,757
-16% -$309K 0.15% 66
2021
Q4
$2.21M Buy
17,044
+383
+2% +$44.7K 0.17% 54
2021
Q3
$1.89M Buy
16,661
+824
+5% +$94.1K 0.15% 59
2021
Q2
$1.64M Sell
15,837
-1,346
-8% -$127K 0.14% 59
2021
Q1
$1.44M Sell
17,183
-168
-1% -$14.2K 0.13% 63
2020
Q4
$1.58M Sell
17,351
-1,442
-8% -$120K 0.16% 58
2020
Q3
$1.5M Buy
18,793
+243
+1% +$19K 0.17% 57
2020
Q2
$1.28M Sell
18,550
-134
-0.7% -$9.52K 0.15% 65
2020
Q1
$1.18M Sell
18,684
-321
-2% -$23.1K 0.16% 68
2019
Q4
$1.48M Buy
19,005
+2,328
+14% +$182K 0.16% 80
2019
Q3
$1.22M Buy
+16,677
New +$1.17M 0.17% 81

Other funds holding EW

NorthRock Partners's EW Position: Q1 2026 in Review

NorthRock Partners reduced its Edwards Lifesciences (EW) stake by 3.4% in Q1 2026, selling an estimated $46.7K and leaving 16,038 shares worth $1.28M. The position accounts for 0.02% of the portfolio, ranked #258.

NorthRock Partners first reported a position in EW in Q3 2019 and has held it in 27 quarters since. The position peaked at $2.21M in Q4 2021. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • NorthRock Partners held 16,038 shares of Edwards Lifesciences worth $1.28M as of Q1 2026.
  • NorthRock Partners sold 567 Edwards Lifesciences shares in Q1 2026, an estimated $46.7K.
  • Edwards Lifesciences made up 0.02% of NorthRock Partners's portfolio in Q1 2026, its #258 holding.
  • NorthRock Partners first reported a position in Edwards Lifesciences in Q3 2019 and has held it in 27 quarters since.
  • NorthRock Partners's Edwards Lifesciences position peaked at $2.21M in Q4 2021.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on NorthRock Partners's 13F filing for Q1 2026, filed 15 May 2026.